Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Simcere Given SFDA Approval for Generic Antibiotic

publication date: May 14, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Simcere Pharmaceutical Group received SFDA approval for a first-to-market generic Biapenem injection, an antibiotic that it will market under the brand name Anxin. Biapenem is a member of the carbenicillin family, and it will compete in the marketplace against brand-name drugs such as Tienam from Merck and Mepem from Sumitomo Pharmaceuticals. Carbenicillins are used in patients who have developed resistance to other antibiotics.  More details...

Stock Symbols: (NYSE: SCR) (NYSE: MRK)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners